nach oben

Erschienen in:

01.12.2023 | Original Article

Effect of prostaglandin-E1 treatment on pyloric wall thickness in newborns with ductal-dependent critical congenital heart diseases

verfasst von: Umit Ayşe Tandircioglu, Ozlem Boybeyi Turer, Tutku Soyer, Ercan Ayaz, H. Nursun Ozcan, Sule Yigit, Hasan Tolga Celik

Erschienen in: Pediatric Surgery International | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Prostaglandin E1 (PGE1) is used in the medical treatment of ductal-dependent critical congenital heart disease (CCHD) in neonates. Apnea/bradycardia, hypotension, hypokalemia, and fever are the most important side effects of PGE1. Moreover, gastric outlet obstruction has been reported in a few case reports. A prospective study was conducted to investigate the effect of PGE1 treatment on pyloric wall thickness in newborns with congenital heart diseases.

Methods

A total of 22 newborns with ductal-dependent CCHD having PGE1 infusion longer than a week were included in this study. Ultrasonographic measurements were performed before and one week after the PGE1 infusion to evaluate the pyloric thickness and length. The protocol was registered with ClinicalTrials.govidentifier NCT04496050.

Results

A total of 22 neonates with mean gestational age 38 ± 1.8 weeks and birth weight 3105 ± 611 gr were enrolled in the study. The median time of the second ultrasound was seven days. The median cumulative dose of PGE1 given during this period was 108 mcg/kg/min. There was a statistically significant increase in post-treatment pyloric thickness and length compared to pre-treatment measurements (p < 0.001, p < 0.001). None of the patients with increased thickness and pyloric muscle length presented any symptoms.

Conclusion

PGE1 treatment significantly increased the pyloric thickness and length after at least one-week treatment. PGE1 with its action mechanism is likely to cause gastric outlet obstruction, although not exactly pyloric stenosis on the condition used for a long time.

Rohit M, Rajan P (2020) Approach to cyanotic congenital heart disease in children. Indian J Pediatr 87:372–380. https://doi.org/10.1007/s12098-020-03274-3CrossRefPubMed

Sadowski SL (2015) Cardiovascular disorders. In: Verklan MT, Walden M (eds) Core curriculum for neonatal intensive care nursing, 5th edn. Elsevier, St. Louis, MO, pp 527–582

Alhussin W, Verklan MT (2016) Complications of long-term prostaglandin E1 use in newborns with ductal-dependent critical congenital heart disease. J Perinat Neonatal Nurs 30:73–79. https://doi.org/10.1097/JPN.0000000000000152CrossRefPubMed

Shepherd J, Hsu KH, Noori S (2018) Variable role of patent ductus arteriosus. Semin Fetal Neonatal Med 23:273–277CrossRefPubMed

Callahan MJ, McCauley RG, Patel H, Hijazi ZM (1999) The development of hypertrophic pyloric stenosis in a patient with prostaglandin-induced foveolar hyperplasia. Pediatr Radiol 29:748–751. https://doi.org/10.1007/s002470050688CrossRefPubMed

Vinycomb TI, Laslett K, Gwini SM et al (2019) Presentation and outcomes in hypertrophic pyloric stenosis: an 11 year review. J Paediatr Child Health 55:1183–1187. https://doi.org/10.1111/jpc.14372CrossRefPubMed

Calle-Toro JS, Kaplan SL, Andronikou S (2020) Are we performing ultrasound measurements of the wall thickness in hypertrophic pyloric stenosis studies the same way? Pediatr Surg Int 36:399–405. https://doi.org/10.1007/s00383-019-04601-2CrossRefPubMed

Boybeyi-Turer O, Celik HT, Arslan UE, Soyer T, Tanyel FC, Kiran S (2022) Environmental exposure in the etiology of infantile hypertrophic pyloric stenosis: a systematic review and meta-analysis. Pediatr Surg Int 38:951–961. https://doi.org/10.1007/s00383-022-05128-9CrossRefPubMed

Canfield MA, Ramadhani TA, Yuskiv N et al (2006) Centers for disease control and prevention (CDC). Improved national prevalence estimates for 18 selected major birth defects-United States, 1999–2001. MMWR Morbidite Mortalite Weekly Rep 54:1301–1305

10.

Ossa Galvis MM, Bhakta RT, Tarmahomed A et al (2022) Cyanotic heart disease 2021. StatPearls Publishing, Treasure Island (FL)

11.

Xie D, Fang J, Liu Z et al (2018) Epidemiology and major subtypes of congenital heart defects in Hunan Province China. Medicine (Baltimore) 97:e11770. https://doi.org/10.1097/MD.0000000000011770CrossRefPubMed

12.

Khoshhal SQ, Albasri AM, Morsy MMF et al (2020) The trends and patterns of congenital heart diseases at Madinah Cardiac Center, Madinah. Saudi Arabia Saudi Med J 41:977–983. https://doi.org/10.15537/smj.2020.9.25275CrossRefPubMed

13.

Namuyonga J, Lubega S, Aliku T et al (2020) Pattern of congenital heart disease among children presenting to the Uganda Heart Institute, Mulago Hospital: a 7 year review. Afr Health Sci 20:745–752. https://doi.org/10.4314/ahs.v20i2.26CrossRefPubMedPubMedCentral

14.

Coceani F, Olley PM (1973) The response of the ductus arteriosus to prostaglandins. Can J Physiol Pharmacol 51:220–225. https://doi.org/10.1139/y73-031CrossRefPubMed

15.

Huang FK, Lin CC, Huang TC et al (2013) Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation. Pediatr Neonatol 54:102–106. https://doi.org/10.1016/j.pedneo.2012.10.007CrossRefPubMed

16.

Peled N, Dagan O, Babyn P et al (1992) Gastric-outlet obstruction induced by prostaglandin therapy in neonates. N Engl J Med 20(327):505–510. https://doi.org/10.1056/NEJM199208203270801CrossRef

17.

Perme T, Mali S, Vidmar I et al (2013) Prolonged prostaglandin E1 therapy in a neonate with pulmonary atresia and ventricular septal defect and the development of antral foveolar hyperplasia and hypertrophic pyloric stenosis. Ups J Med Sci 118:138–142. https://doi.org/10.3109/03009734.2013.778374CrossRefPubMedPubMedCentral

18.

Soyer T, Yalcin S, Bozkaya D et al (2014) Transient hypertrophic pyloric stenosis due to prostoglandin infusion. J Perinatol 34:800–801. https://doi.org/10.1038/jp.2014.101CrossRefPubMed

19.

Tálosi G, Katona M, Túri S (2007) Side-effects of long-term prostaglandin E1 treatment in neonates. Pediatr Int 49:335–340. https://doi.org/10.1111/j.1442-200X.2007.02380.xCrossRefPubMed

20.

Lacher M, Schneider K, Dalla Pozza R et al (2007) Gastric outlet obstruction after long-term prostaglandin administration mimicking hypertrophic pyloric stenosis. Eur J Pediatr Surg 17:362–364. https://doi.org/10.1055/s-2007-965422CrossRefPubMed

21.

Kosiak W, Swieton D, Fryze I et al (2009) Gastric outlet obstruction due to an iatrogenic cause in a neonatal period—report of two cases. Ultraschall Med 30(4):401–403. https://doi.org/10.1055/s-2007-963282CrossRefPubMed

22.

Boybeyi O, Soyer T, Atasoy P et al (2015) Investigation of the effects of enteral hormones on the pyloric muscle in newborn rats. J Pediatr Surg 50:408–412. https://doi.org/10.1016/j.jpedsurg.2014.05.036CrossRefPubMed

Titel: Effect of prostaglandin-E1 treatment on pyloric wall thickness in newborns with ductal-dependent critical congenital heart diseases
verfasst von: Umit Ayşe Tandircioglu
Ozlem Boybeyi Turer
Tutku Soyer
Ercan Ayaz
H. Nursun Ozcan
Sule Yigit
Hasan Tolga Celik
Publikationsdatum: 01.12.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Surgery International / Ausgabe 1/2023
Print ISSN: 0179-0358
Elektronische ISSN: 1437-9813
DOI: https://doi.org/10.1007/s00383-023-05428-8

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Effect of prostaglandin-E1 treatment on pyloric wall thickness in newborns with ductal-dependent critical congenital heart diseases